ストックスクリーナーアプリを入手
127.18
2.49%
3.09
アフターアワーズ：
127.33
0.15
+0.12%
Gilead Sciences Inc (GILD) 最新ニュース
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead joins partners for delivery of first shipments of breakthrough twice-yearly lenacapavir for HIV prevention to sub-Saharan Africa - European AIDS Treatment Group
Gilead Sciences’ (GILD) chief commercial officer sells $3.5m in stock - Investing.com UK
Raiffeisen Bank International AG Trims Position in Gilead Sciences, Inc. $GILD - MarketBeat
Nomura Asset Management Co. Ltd. Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD is LSV Asset Management's 9th Largest Position - MarketBeat
Thoroughbred Financial Services LLC Has $1.10 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Ontario Teachers Pension Plan Board - MarketBeat
Gilead Sciences, Inc. $GILD Position Boosted by Citizens Financial Group Inc. RI - MarketBeat
Gilead (GILD) Begins Shipments of HIV Prevention Drug to Africa - GuruFocus
Gilead ships first lenacapavir doses to sub-Saharan Africa - StreetInsider
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa - Business Wire
Cetera Investment Advisers Purchases 21,966 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3... - Medical Dialogues
Before GLP-1s, a Great Pricing Battle Played Out in Hep C Market - BioSpace
Is It Too Late to Reassess Gilead After Recent Drug Trial Success? - simplywall.st
Will Gilead Sciences Inc. stock deliver long term returnsJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
Gilead Sciences's Options: A Look at What the Big Money is Thinking - Benzinga
Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Raised by Westpac Banking Corp - MarketBeat
Letko Brosseau & Associates Inc. Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Persistent Asset Partners Ltd Invests $767,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Foundations Investment Advisors LLC Buys 17,318 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Creative Planning Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Where speed meets science in Gilead’s approach to drug development - Endpoints News
Crossmark Global Holdings Inc. Sells 39,563 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Cornerstone Advisors LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Avantax Advisory Services Inc. - MarketBeat
Alberta Investment Management Corp Lowers Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Will Gilead Sciences Inc. (GIS) stock outperform energy sector in 2025Weekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Westwood Holdings Group Inc. Acquires 11,145 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Intech Investment Management LLC Buys 74,506 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
OmniStar Financial Group Inc. Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Intrua Financial LLC Sells 4,494 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock outperform Dow JonesWeekly Earnings Recap & Verified Momentum Stock Alerts - newser.com
Arvest Bank Trust Division Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Advisors Capital Management LLC Cuts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded at Wall Street Zen - MarketBeat
Scotiabank Analyst Sees Opportunity in Large Cap Biopharma, Keeps Outperform on GILD - Finviz
Will Gilead Sciences Inc. stock sustain high P E ratiosJuly 2025 Trade Ideas & Verified Entry Point Detection - newser.com
Ethiopia confirms first outbreak of Marburg virus after testing - The Spokesman-Review
Insider Selling: Gilead Sciences (NASDAQ:GILD) EVP Sells 53,646 Shares of Stock - MarketBeat
Using data tools to time your Gilead Sciences Inc. exitPortfolio Gains Report & Real-Time Sentiment Analysis - newser.com
Zacks Research Forecasts Lower Earnings for Gilead Sciences - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Wrapmanager Inc. - MarketBeat
Gilead Sciences (NASDAQ:GILD) Raised to Strong-Buy at Scotiabank - MarketBeat
Grandfield & Dodd LLC Has $24.50 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Is this a good reentry point in Gilead Sciences Inc.2025 Macro Impact & Breakout Confirmation Trade Signals - newser.com
PNC Financial Services Group Inc. Purchases 8,023 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
ABN Amro Investment Solutions Takes $5.30 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Nasdaq Today Shows Drug-Innovation - Kalkine Media
Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views - Insider Monkey
Needham & Company LLC Increases Gilead Sciences (NASDAQ:GILD) Price Target to $140.00 - MarketBeat
Is Gilead Sciences Inc. (GIS) stock dividend growth reliableRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Daiwa Capital Markets Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (NASDAQ:GILD) Coverage Initiated at Scotiabank - MarketBeat
Wealth Alliance LLC Has $1.16 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Impax Asset Management Group plc - MarketBeat
Police & Firemen s Retirement System of New Jersey Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead scores clinical trial win toward moving HIV patients from multiple-drug regimen to single tablet - The Business Journals
Gilead Sciences, Inc. $GILD Shares Sold by M&G PLC - MarketBeat
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill - BioSpace
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal - TradingView
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial - Yahoo
Is Gilead’s Successful Phase 3 HIV Regimen Trial Shifting the Investment Case for GILD? - Yahoo Finance
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial - BioSpace
Is Gilead Sciences Inc. (GIS) stock inflation resilientTreasury Yields & Risk Managed Investment Strategies - Fundação Cultural do Pará
Credit Capital Investments LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Candriam S.C.A. - MarketBeat
Gilead Sciences Insider Sold Shares Worth $6,590,487, According to a Recent SEC Filing - MarketScreener
Gilead Sciences EVP Telman sells $6.59 million in stock By Investing.com - Investing.com Nigeria
Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV - Stocktwits
Gilead Sciences EVP Telman sells $6.59 million in stock - Investing.com India
Can Gilead Sciences Inc. stock continue upward trendJuly 2025 Action & Pattern Based Trade Signal System - newser.com
0.34%
0.53%
大文字化:
|
ボリューム (24 時間):